Literature DB >> 7363932

Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents.

E Richter, D D Breimer, W Zilly.   

Abstract

The pharmacokinetics of intravenously infused hexobarbital was studied in 10 patients with intrahepatic cholestasis and in 9 with extrahepatic biliary obstruction. The results were compared with those obtained in 16 healthy young volunteers and 5 older patients with normal liver function. After infusion, the plasma concentrations showed a rapid initial decline (alpha-phase) and subsequently a slower decrease (beta-phase). The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively. The differences were not statistically significant. The mean volume of the central compartment of distribution and the steady state volume of distribution were not significantly different. In two patients hexobarbital clearance during cholestasis was greater than after it had subsided. After treatment of 11 patients with cholestasis with drug metabolism-inducing agents (phenobarbital, rifampicin or phenytoin), the half-life of hexobarbital was significantly shortened and the mean value of hexobarbital clearance was more than doubled.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7363932     DOI: 10.1007/bf00561900

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  28 in total

1.  Hexobarbital sleeping time and drug metabolism in rats with ligated bile ducts--a lack of correlation.

Authors:  R Drew; B G Priestly
Journal:  Biochem Pharmacol       Date:  1976-07-15       Impact factor: 5.858

2.  Stimulation of drug metabolism by rifampicin in patients with cirrhosis or cholestasis measured by increased hexobarbital and tolbutamide clearance.

Authors:  W Zilly; D D Breimer; E Richter
Journal:  Eur J Clin Pharmacol       Date:  1977-04-20       Impact factor: 2.953

3.  Cholestasis is the result of hypoactive hypertrophic smooth endoplasmic reticulum in the hepatocyte.

Authors:  F Schaffner; H Popper
Journal:  Lancet       Date:  1969-08-16       Impact factor: 79.321

4.  [Drug metabolism in experimental cholestasis].

Authors:  E Richter; M Grün; W Zilly; D Brachtel; H A Kühn
Journal:  Verh Dtsch Ges Inn Med       Date:  1972

5.  Hexobarbital disposition in compensated and decompensated cirrhosis of the liver.

Authors:  W Zilly; D D Breimer; E Richter
Journal:  Clin Pharmacol Ther       Date:  1978-05       Impact factor: 6.875

6.  Bile acid glucuronides, II[1]. Isolation and identification of a chenodeoxycholic acid glucuronide from human plasma in intrahepatic cholestasis.

Authors:  P Back
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1976-02

7.  Sulphated and unsulphated bile acids in serum, bile, and urine of patients with cholestasis.

Authors:  G P van Berge Henegouwen; K H Brandt; H Eyssen; G Parmentier
Journal:  Gut       Date:  1976-11       Impact factor: 23.059

8.  Pharmocokinetics of hexobarbital in man after intravenous infusion.

Authors:  D D Breimer; C Honhoff; W Zilly; E Richter; J M van Rossum
Journal:  J Pharmacokinet Biopharm       Date:  1975-02

9.  Alternative transport pathways of cholephilic 14C-hexobarbital metabolites in rats with experimental hepatitis and cholestasis.

Authors:  E Richter; R Joeres; J Buschmann; W Zilly
Journal:  Acta Hepatogastroenterol (Stuttg)       Date:  1979-12

10.  Determinants of serum antipyrine half-lives in patients with liver disease.

Authors:  R A Branch; C M Herbert; A E Read
Journal:  Gut       Date:  1973-07       Impact factor: 23.059

View more
  3 in total

1.  Minimal biliary excretion and enterohepatic recirculation of metoclopramide in patients with extrahepatic cholestasis.

Authors:  A Hellstern; D Hellenbrecht; R Saller; M Gatzen; G Achtert; P Brockmann; H J Hausleiter
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 2.  Drug interactions with phenytoin.

Authors:  E Perucca; A Richens
Journal:  Drugs       Date:  1981-02       Impact factor: 9.546

Review 3.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.